Wang Yixi
Jul 13, 2026
How clinical validation, strategic partnerships and global collaboration are accelerating the commercialisation of healthcare innovation.
The first half of 2026 marked an important period for global healthcare innovation. Across the MedTech sector, stronger investment activity, accelerating clinical validation and evolving regulatory frameworks signalled a new phase in the journey from breakthrough research to real-world adoption.
For IWC, these developments have been reflected across our own ecosystem.
Throughout the past six months, we have continued working alongside portfolio companies, healthcare institutions, research organisations and strategic partners to help bridge the gap between breakthrough innovation and commercialisation. While each milestone represents a different stage of growth, together they demonstrate how collaboration, validation and long-term execution are becoming increasingly important in bringing advanced technologies to patients and global markets.
One of the most significant milestones came from Paradromics, an IWC portfolio company developing next-generation brain-computer interface technology. In June, the company successfully completed the first human implantation of its Connexus® Brain-Computer Interface as part of its FDA-approved Connect-One clinical study in collaboration with the University of Michigan Health. The achievement represents an important step towards restoring communication for people living with severe neurological conditions and highlights how scientific innovation, clinical validation and institutional collaboration can work together to create meaningful patient impact.
Our healthcare portfolio also continued to reach important clinical and commercial milestones. Leo Cancer Care achieved significant progress during the first half of the year, including CE Mark approval for its Marie® upright radiotherapy system, the world's first compact upright proton therapy treatment at Stanford Medicine, and continued expansion of strategic collaborations across the global radiotherapy ecosystem. Collectively, these developments demonstrate the growing clinical adoption of upright radiotherapy and reinforce the importance of long-term validation in transforming breakthrough technologies into standard clinical practice.
Beyond supporting portfolio companies, IWC also continued expanding its collaborative ecosystem.
In May, IWC and Singrass Global visited the Singapore Institute of Technology (SIT) to explore opportunities in sustainable campus development, indoor environmental quality and environmental health. The exchange brought together academia and industry to discuss how environmental technologies and data-driven solutions can contribute to healthier and more sustainable built environments, reinforcing our belief that innovation is accelerated through cross-sector collaboration.
During the same period, IWC CEO Ken Chew shared his perspectives with Lianhe Zaobao on Singapore's evolving role as a strategic platform for technology companies expanding internationally. As global businesses navigate an increasingly complex geopolitical environment, the discussion highlighted the growing importance of governance, regulatory readiness, capital planning and ecosystem integration in enabling sustainable cross-border growth.
Taken together, these milestones reflect a broader evolution taking place across healthcare innovation.
Today, scientific excellence alone is no longer sufficient. Clinical validation, regulatory readiness, strategic partnerships and international execution have become essential components of successful commercialisation. The organisations creating the greatest long-term impact will be those capable of integrating these capabilities while remaining focused on improving patient outcomes.
At IWC, we believe innovation reaches its full potential when supported by the right ecosystem. By connecting founders, investors, healthcare institutions, governments and strategic partners, we continue helping promising technologies move beyond research into meaningful real-world deployment across global markets.
As we look ahead to the second half of 2026, we remain committed to supporting innovators, institutions and partners working at the forefront of healthcare innovation, enabling breakthrough ideas to become scalable solutions that improve lives around the world.